Effects of teriparatide and loading modality on modeling-based and remodeling-based bone formation in the human femoral neck

What Was Tested

The paper reports a study of Teriparatide, published as a randomized controlled trial.

The purpose of the present study was to determine how much of the new bone was formed by modeling-based formation (MBF) or remodeling-based formation (RBF).

Who Took Part

The researchers performed a double-blind trial of TPTD vs. placebo (PBO) in patients about to undergo a total hip replacement (THR) for osteoarthritis.

Sites of new bone formation were identified by the presence of tetracycline labels and designated as MBF if the underlying cement line was smooth and as RBF if it was scalloped.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Teriparatide and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Teriparatide.

A placebo (an inactive look-alike) gave the Teriparatide group a baseline to be compared against.

After an average of 3 weeks of study drug, double tetracycline labels were administered per standard protocol.

Histomorphometric analysis was performed in the cancellous, endocortical, and periosteal envelopes.

Additionally, separate analyses were performed in the tensile and compressive regions of the endocortical and periosteal envelopes.

New bone formation on smooth cement lines adjacent to scalloped reversal lines was designated as overflow RBF (oRBF).

The referent for all indices was bone surface (BS).

What Was Measured

PubMed files the paper under topics including Bone Density, Bone Density Conservation Agents, Femur Neck, Osteogenesis, Teriparatide and Tetracyclines.

Author keywords: Compression, Femoral neck, Modeling, Remodeling and Tension.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Teriparatide.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (Bone), a journal based in United States.

More context: the Teriparatide compound page, all human trials.